NEW YORK – Sept. 1, 2015 – Four shareholders from the international law firm Greenberg Traurig, LLP have been named “Life Science Stars” in LMG Life Sciences 2015 guide.
The guide serves as a resource for in-house counsel identifying leading lawyers and firms in multiple practice areas. These practice areas include intellectual property, regulatory, transactional, and non-IP litigation, which play important roles in guiding a product through its lifecycle.
The following Greenberg Traurig shareholders were selected:
Scott J. Bornstein is chair of Greenberg Traurig’s New York Intellectual Property & Technology Practice and co-chair of the firm’s Global Patent Litigation Group. He has broad experience in patent, trademark, and copyright litigation; licensing; and general IP counseling for a wide variety of national and international clients. Bornstein has tried eight patent cases as lead or co-lead counsel and has participated in approximately 20 patent trials. Bornstein also has wide-ranging experience working with clients to develop prosecution and enforcement strategies which support their business objectives.
Lori G. Cohen is chair of the firm’s national Pharmaceutical, Medical Device & Health Care Litigation and National Trial practices as well as co-chair of the Atlanta Litigation Practice. Cohen’s national practice focuses on products liability litigation, and specifically, medical device and pharmaceutical litigation. She has obtained 56 defense verdicts at trial, and she has been profiled by many publications as a top trial attorney.
David J. Dykeman is co-chair of the firm’s global Life Sciences & Medical Technology Group and a co-chair of the firm’s Boston Intellectual Property & Technology Practice. A registered patent attorney with nearly 20 years of experience in patents, intellectual property, and licensing, Dykeman focuses his practice on securing strategic worldwide intellectual property protection and related business strategy for high-tech clients, with particular expertise in medical devices, life sciences, biotechnology, and health care IT.
Eric Hargan is a shareholder in the firm’s Health & FDA Business Practice, previously serving as U.S. Department of Health and Human Services deputy secretary and chief regulatory officer. Hargan focuses his practice on transactions, health care regulations, and government relations. Within the transactional area, he has over 20 years of experience as a corporate lawyer in private equity, corporate finance, and mergers and acquisitions transactions.
According to its website, LMG Life Sciences’ research involved over 1,000 online surveys and interviews with nearly 600 attorneys in the United States, as well as a review of public information and feedback from clients within the industry. This qualitative process of peer opinion, market feedback, and independent research led to their list of highest profile, most sought-after, and best-attorneys working in life sciences.